Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Closing Down mTOR Signaling Prevents Prostate Tumor Metastasis

By LabMedica International staff writers
Posted on 12 Mar 2012
An experimental drug the blocks the activity of the molecular pathway moderated by the mTOR (mammalian target of rapamycin) kinase enzyme prevented prostate tumor metastasis in a mouse model of the disease.

mTOR is a master regulator of protein synthesis that under ordinary conditions induces cells to grow and divide. More...
In situations of severe nutrient deprivation, mTOR closes down protein synthesis so that the cell can conserve energy. However, in cancer cells the mTOR pathway misfires and signals tumor cells to grow, divide, undergo metastasis, and invade new, healthy tissues.

Investigators at the University of California, San Francisco (USA) sought to identify the proteins controlled by mTOR signaling in order to understand better how it could be targeted by drugs that would block this activity.

The investigators reported in the February 22, 2012, online edition of the journal Nature that by using an advanced ribosome profiling technique, they had uncovered specialized translation of the prostate cancer genome by oncogenic mTOR signaling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism, and invasion. They extended these findings by functionally characterizing a class of translationally controlled proinvasion messenger RNAs that directed prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling. In addition, they developed a clinically relevant ATP site inhibitor of mTOR, INK128, which reprogrammed this gene expression signature with therapeutic benefit for prostate cancer metastasis.

"We are now discovering that during tumor formation mTOR leads to metastasis by altering the synthesis of a specific group of proteins that make the cancer cells move and invade normal organs,” said senior author Dr. Davide Ruggero, associate professor of urology at the University of California, San Francisco. "Many human cancers show hyperactivation of this pathway. Until now, we have not known how hyperactive mTOR perturbs the synthesis of certain proteins leading to fatal cancer. Deregulations in protein synthesis are now becoming a hallmark of cancer, and we are very excited by the opportunity to target the aberrant protein synthesis apparatus in many cancers."

Related Links:
University of California, San Francisco


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.